Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVSEF) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to $11.6 billion.

  • Novartis Ag's Cash & Current Investments fell 1387.38% to $11.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $11.6 billion, marking a year-over-year decrease of 1387.38%. This contributed to the annual value of $11.6 billion for FY2025, which is 1387.38% down from last year.
  • Per Novartis Ag's latest filing, its Cash & Current Investments stood at $11.6 billion for Q4 2025, which was down 1387.38% from $9.6 billion recorded in Q3 2025.
  • Novartis Ag's 5-year Cash & Current Investments high stood at $6000.3 billion for Q1 2021, and its period low was $5.0 billion during Q1 2022.
  • Its 5-year average for Cash & Current Investments is $312.6 billion, with a median of $11.9 billion in 2023.
  • In the last 5 years, Novartis Ag's Cash & Current Investments soared by 115158445.3% in 2021 and then crashed by 9991.61% in 2022.
  • Over the past 5 years, Novartis Ag's Cash & Current Investments (Quarter) stood at $28.3 billion in 2021, then plummeted by 33.18% to $18.9 billion in 2022, then decreased by 23.78% to $14.4 billion in 2023, then dropped by 6.73% to $13.5 billion in 2024, then decreased by 13.87% to $11.6 billion in 2025.
  • Its last three reported values are $11.6 billion in Q4 2025, $9.6 billion for Q3 2025, and $7.0 billion during Q2 2025.